ELECTROPHYSIOLOGIC DETERMINANTS OF PHARMACOLOGICAL CONVERSION OF HUMAN ATRIAL-FIBRILLATION AND FLUTTER - ENHANCED EFFICACY OF IBUTILIDE A NEW CLASS-III ANTIARRHYTHMIC DRUG

被引：0
|
作者：
STAMBLER, BS [1 ]
WOOD, MA [1 ]
BELZ, MK [1 ]
SPERRY, RE [1 ]
VANDERLUGT, JT [1 ]
ELLENBOGEN, KA [1 ]
机构：
[1] VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,MCGUIRE VA MED CTR,RICHMOND,VA 23298
来源：
CIRCULATION | 1993年 / 88卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：445 / 445
页数：1
相关论文
共 31 条
  • [1] CLASS-III ANTIARRHYTHMIC ACTION IN EXPERIMENTAL ATRIAL-FIBRILLATION AND FLUTTER IN DOGS
    PLATOU, ES
    REFSUM, H
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1982, 4 (05) : 839 - 846
  • [2] EFFICACY AND SAFETY OF A NEW SELECTIVE CLASS-III ANTIARRHYTHMIC AGENT DOFETILIDE IN PAROXYSMAL ATRIAL-FIBRILLATION OR ATRIAL-FLUTTER
    SUTTORP, MJ
    POLAK, PE
    VANTHOF, A
    RASMUSSEN, HS
    DUNSELMAN, PH
    KINGMA, JH
    AMERICAN JOURNAL OF CARDIOLOGY, 1992, 69 (04): : 417 - 419
  • [3] Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation - Electrophysiological determinants of enhanced conversion efficacy
    Stambler, BS
    Wood, MA
    Ellenbogen, KA
    CIRCULATION, 1997, 96 (12) : 4298 - 4306
  • [4] TREATMENT OF ATRIAL-FIBRILLATION WITH CLASS-III ANTIARRHYTHMIC DRUGS
    FOLLATH, F
    CANDINAS, R
    FRIELINGSDORF, J
    HERZ, 1993, 18 (01) : 20 - 26
  • [5] INDICATIONS AND LIMITATIONS OF CLASS-II AND CLASS-III ANTIARRHYTHMIC DRUGS IN ATRIAL-FIBRILLATION
    HOHNLOSER, SH
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1994, 17 (05): : 1019 - 1025
  • [6] ATRIAL-FLUTTER CAN BE TERMINATED BY A CLASS-III ANTIARRHYTHMIC DRUG BUT NOT BY A CLASS-IC DRUG
    CRIJNS, HJGM
    VANGELDER, IC
    KINGMA, JH
    DUNSELMAN, PHJM
    GOSSELINK, ATM
    LIE, KI
    EUROPEAN HEART JOURNAL, 1994, 15 (10) : 1403 - 1408
  • [7] Refralon (niferidil) is a new class III antiarrhythmic agent for pharmacological cardioversion for persistent atrial fibrillation and atrial flutter
    Maykov, E. B.
    Yuricheva, Yu. A.
    Mironov, N. Yu.
    Sokolov, S. F.
    Golitsyn, S. P.
    Rozenshtraukh, L. V.
    Chazov, E. I.
    TERAPEVTICHESKII ARKHIV, 2015, 87 (01) : 38 - 48
  • [8] Electrophysiologic effects of the new class III antiarrhythmic drug dofetilide compared to the class IA antiarrhythmic drug quinidine in experimental canine atrial flutter: Role of dispersion of refractoriness in antiarrythmic efficacy
    Cha, YM
    Wales, A
    Wolf, P
    Shahrokni, S
    Sawhney, N
    Feld, GK
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 1996, 7 (09) : 809 - 827
  • [9] CLASS-III ANTIARRHYTHMIC DRUG-ACTION IN EXPERIMENTAL ATRIAL-FIBRILLATION - DIFFERENCES IN REVERSE USE DEPENDENCE AND EFFECTIVENESS BETWEEN D-SOTALOL AND THE NEW ANTIARRHYTHMIC DRUG AMBASILIDE
    WANG, JJ
    FENG, JL
    NATTEL, S
    CIRCULATION, 1994, 90 (04) : 2032 - 2040
  • [10] Efficacy of a New Class III Drug Niferidil in Cardioversion of Persistent Atrial Fibrillation and Flutter
    Maykov, Evgeny B.
    Yuricheva, Yulia A.
    Mironov, Nikolay Yu
    Sokolov, Sergey F.
    Golitsyn, Sergey P.
    Rosenshtraukh, Leonid V.
    Chazov, Evgeny I.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2014, 64 (03) : 247 - 255
1234